Aplastic anemia is a rare and serious blood disorder in which your bone marrow stops producing enough new blood cells. Unlike other forms of anemia that involve only red blood cells, aplastic anemia typically affects all three major blood cell types: red cells, white cells, and platelets. This across-the-board shortage, called pancytopenia, is what makes the condition particularly dangerous. It occurs in roughly 1.5 to 7 people per million each year, with higher rates in East Asia (over 4 per million) compared to Europe and the United States.
How Bone Marrow Failure Develops
In a healthy person, bone marrow is a bustling factory filled with stem cells that constantly replenish your blood supply. In aplastic anemia, those stem cells are destroyed or suppressed, and the marrow becomes abnormally empty. A bone marrow biopsy in someone with severe aplastic anemia typically shows cellularity below 30%, meaning most of the space that should be packed with developing blood cells is instead filled with fat.
The leading explanation for how this happens is an immune system attack on the body’s own stem cells. Your immune system’s killer T cells, which normally target viruses and bacteria, become misdirected and begin destroying the stem cells in your bone marrow. Researchers have found significantly elevated levels of these activated killer T cells in both the blood and bone marrow of people with aplastic anemia. In lab studies, T cells taken from untreated patients killed up to 75% of bone marrow cells when the two were placed together.
These rogue T cells also release inflammatory signaling molecules that further suppress blood cell production. Two of these signals in particular drive stem cells into a self-destruct process called apoptosis, essentially programming the cells to die. The result is a bone marrow that progressively loses its ability to keep up with the body’s demand for fresh blood cells.
Known Triggers and Causes
In most cases, the exact trigger that sets off the immune attack is never identified. This is called idiopathic aplastic anemia, and it accounts for the majority of diagnoses. However, several known triggers can provoke the condition:
- Viral infections: Hepatitis viruses (sometimes ones that don’t match any known hepatitis type), Epstein-Barr virus, and HIV have all been linked to bone marrow failure.
- Chemical exposures: Benzene, a solvent found in some industrial settings, is one of the most well-established environmental causes.
- Medications: Certain drugs, including some antibiotics and anti-seizure medications, can trigger the condition in susceptible individuals.
- Radiation and chemotherapy: These treatments intentionally damage rapidly dividing cells, and bone marrow stem cells are particularly vulnerable.
Genetic susceptibility plays a role too. Certain immune system gene variants (specific HLA types) appear more frequently in people who develop aplastic anemia, suggesting that some individuals are biologically primed for their immune system to turn against their own marrow when exposed to the right trigger.
What It Feels Like
The symptoms of aplastic anemia reflect the shortage of each type of blood cell, and they often develop gradually enough that people attribute them to stress or aging before getting a diagnosis.
Low red blood cells cause persistent, deep fatigue that doesn’t improve with rest. You might feel short of breath during activities that previously felt easy, and your skin may look noticeably pale. Low platelets lead to unusual bruising, tiny red or purple dots on the skin called petechiae, bleeding gums, and nosebleeds that are hard to stop. Cuts may bleed longer than expected. Low white blood cells, particularly a type called neutrophils, leave you vulnerable to frequent or severe infections. A routine cold might hit harder than usual, or you might develop fevers without an obvious source.
Because the onset is often slow, some people have significantly low blood counts by the time they see a doctor. Others are diagnosed incidentally when routine blood work reveals unexpectedly low numbers across all cell lines.
How Severity Is Classified
Doctors classify aplastic anemia as moderate, severe, or very severe based on specific blood count thresholds known as the Camitta criteria. Severe aplastic anemia requires bone marrow cellularity below 30% plus at least two of the following: a neutrophil count under 500 per microliter, a platelet count under 20,000 per microliter, or a proportion of young red blood cells (reticulocytes) below 1%. Very severe aplastic anemia uses the same criteria but with neutrophils below 200 per microliter. These cutoffs matter because they determine which treatment path is recommended.
Distinguishing It From Similar Conditions
One of the trickiest diagnostic challenges is telling aplastic anemia apart from a related condition called myelodysplastic syndrome (MDS), which can also cause low blood counts and a sparse-looking marrow. The distinction matters because the two conditions are treated differently and carry different risks.
In aplastic anemia, the chromosomes in bone marrow cells are normal, and there are no blast cells (immature cells that can signal cancer). The marrow looks empty but otherwise healthy. In MDS, about half of patients show abnormal chromosomes, and there are often visible abnormalities in how blood cells are maturing, particularly in platelets’ precursor cells and in white blood cell appearance. The presence of any significant blast cells essentially rules out aplastic anemia and points toward MDS. Specialized staining can also reveal ringed sideroblasts and increased fibrosis, both more characteristic of MDS.
Treatment: Two Main Paths
Treatment for aplastic anemia follows one of two main strategies depending on your age, disease severity, and whether a matched donor is available.
Bone Marrow Transplant
For younger patients with severe disease who have a matched sibling donor, a bone marrow (or stem cell) transplant is the preferred treatment. This replaces the failing marrow with healthy donor stem cells that can rebuild blood production from scratch. Outcomes have improved substantially over the past two decades. Patients who received transplants between 2011 and 2018 saw their risk of death become comparable to the general population’s within about five years. Long-term survival exceeds 80% for patients who make it through the first year.
Immunosuppressive Therapy
For patients who lack a matched donor or who are older (typically over 40), the standard approach is calming the immune attack rather than replacing the marrow. The backbone of this treatment combines two medications: one that depletes the destructive T cells and another that keeps them suppressed long-term. This combination produces a meaningful response in 50 to 60% of patients, with about 60% overall survival at one year. Treatment requires hospitalization for the initial phase, which lasts several days, followed by months of outpatient monitoring.
Adding a medication that stimulates platelet production has significantly improved these numbers. A trial published in the New England Journal of Medicine found that patients who received this addition alongside standard immunosuppression had an overall response rate of 68% at six months, compared to 41% with immunosuppression alone. Complete response rates more than doubled, from 10% to 22% at three months.
Living With Aplastic Anemia
Day-to-day life with aplastic anemia, particularly during and after treatment, revolves around managing low blood counts and avoiding complications. When your neutrophil count is very low, infection prevention becomes a central concern. This means being vigilant about hand washing, avoiding crowds during cold and flu season, staying away from people who are sick, and paying attention to any sign of fever or infection since your body may not mount the usual warning signs.
Fatigue is one of the most persistent challenges. Many patients find they need to restructure their daily routines around their energy levels, building in rest periods and accepting a slower pace. Blood transfusions may be needed periodically to manage severe anemia or dangerously low platelet counts while waiting for treatment to take effect.
Nutritionally, a diet rich in dark leafy greens, nuts, dried fruit, red meat, whole grains, citrus fruits, and beans can support blood cell production, though diet alone cannot overcome the marrow failure. It complements medical treatment rather than replacing it.
The good news is that outcomes have improved markedly. For patients who survive the critical first year after either transplant or immunosuppressive therapy, long-term survival exceeds 80%. Patients treated in recent years who receive transplants reach a life expectancy comparable to the general population within five years of their procedure. Even those treated with immunosuppression see their survival odds converge with the general population over time, though the timeline is somewhat longer.